The higher level of expression of RAB3A, SYP, CAMK2A, and GABRA1 in glioma patients was associated with improved OS and DFS (Figures 6(a), 6(a)-6(d), 6(f)-6(g), 6(i)-6(j), and 6(l)), whereas the higher level of expression of TYROBP and VSIG4 was associated with reduced OS and DFS (Figures 6(b), 6(e), 6(h), and 6(k)). Here, TYROBP is linked to central nervous system cancer.